Peptides Codex
ENFR
← Home
Incretin triple agonist

Retatrutide

Retatrutide is an investigational triple agonist peptide targeting GLP-1, GIP, and glucagon receptors. It is widely discussed in metabolic research and news, and is a high-intent educational search topic.

By The Peptides Codex Editorial TeamReviewed July 10, 2026
Length
39 aa
Class
Incretin triple agonist
Function
GLP-1 / GIP / glucagon receptor triple agonist (investigational/clinical research)
Context
Clinical development for metabolic disease; not a general consumer product

Triple-agonist metabolic peptide — high search volume, clinical-stage science.

Also known as: LY3437943 · triple agonist

Part of the Metabolic & GLP-1 peptides cluster

Overview

Retatrutide is an investigational triple agonist peptide targeting GLP-1, GIP, and glucagon receptors. It is widely discussed in metabolic research and news, and is a high-intent educational search topic.

Source & context

Biological / chemical source: Synthetic engineered peptide

Primary research or clinical context: Clinical development for metabolic disease; not a general consumer product

Why three receptors

Adding glucagon receptor activity to incretin agonism is hypothesized to increase energy expenditure while retaining appetite and glycemic effects — a design thesis driving intense clinical interest.

Status literacy

Availability and approval status change over time by country. Always distinguish peer-reviewed clinical data and regulatory status from unregulated research chemicals sold online under the same name.

FAQ about Retatrutide

What is Retatrutide?+

Retatrutide is an investigational triple agonist peptide targeting GLP-1, GIP, and glucagon receptors. It is widely discussed in metabolic research and news, and is a high-intent educational search topic.

Is Retatrutide an approved medicine?+

Retatrutide is discussed here as a research / educational topic. Clinical development for metabolic disease; not a general consumer product. This is not medical advice.

What is the typical length of Retatrutide?+

Retatrutide is commonly described as approximately 39 amino acids (Incretin triple agonist).

Related peptides

BPC-157
Research peptide
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide studied in preclinical models of tissue repair and gastrointestinal protection. It is not an approved therapeutic in Canada or the United States.
TB-500
Research peptide
TB-500 refers to a synthetic peptide fragment associated with thymosin beta-4 research, studied for effects on cell migration and tissue remodeling in experimental models. It is not an approved medicine.
Tirzepatide
Incretin dual agonist
Tirzepatide is an engineered dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist peptide. It is an approved prescription medicine in multiple jurisdictions and a major case study in multi-receptor peptide design.
GLP-1
Incretin
GLP-1 (glucagon-like peptide-1) is an incretin hormone that stimulates insulin secretion and influences appetite. Engineered analogs dominate modern metabolic medicine research.

References & further reading

  1. 1.Wikipedia — Retatrutide
  2. 2.PubChem — compound summary for Retatrutide (CID 171390338)
  3. 3.Jastreboff et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med
  4. 4.Rosenstock et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet
  5. 5.Urva et al. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet
  6. 6.Sanyal et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med
  7. 7.Coskun et al. (2025). Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol
  8. 8.Kanu et al. (2025). Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study. Diabetes Obes Metab
  9. 9.Urva et al. (2023). The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes Obes Metab
  10. 10.Li et al. (2024). Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discov
  11. 11.Bajaj et al. (2026). Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet
  12. 12.Doggrell (2023). Retatrutide showing promise in obesity (and type 2 diabetes). Expert Opin Investig Drugs
  13. 13.Doggrell (2023). Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?. Expert Opin Investig Drugs
  14. 14.Jakubowska et al. (2024). The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. Endocrinol Metab (Seoul)
  15. 15.Gutgesell et al. (2024). Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes. Diabetes Ther
  16. 16.Katsi et al. (2025). Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules
Disclaimer: Educational content only. Not medical advice. Not instructions for human use. Research peptides and unapproved products may be restricted or illegal to market for human consumption in your jurisdiction. Consult qualified professionals and applicable law.
You might also like: All peptides · Atlas · Research · Tools
Cite this: Peptides Codex — Retatrutide educational profile.
Tip: Use browser print (Ctrl/Cmd + P) for a clean PDF of this page.